-
-
-
-
-
-
-
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
-
-
-
-
-
-
-
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
-
-
-
-
-
-
-
FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Announces Incremental Progress on BLA Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
-
-
-
-
-
-
-
BioMarin Sells Priority Review Voucher for $110 Million
-
-
-
-
-
-
-
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
-
-
-
-
-
-
-
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
-
15,557 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

